Confidential Info Regarding Romidepsin Made Known

The PC20 AMP and eNO measurements were analysed using a mixed effects model with the subject fitted as random effect. The following fixed effects were included in the models: period and treatment group. The data were log (base 2) transformed prior to analyses. For the PC20 AMP, differences and 95% confidence intervals between treatment groups are presented in terms of doubling doses. For the eNO data, the comparisons are presented in terms of a ratio and 95% confidence intervals (FF/placebo or FP/placebo). Differences were considered to be statistically significant when the 2-sided P-value was below 0.05. Twenty-four asthma patients were randomized and 18 completed the study. Baseline characteristics are presented in Table?1. Six patients withdrew from the study: two withdrew their consent, one started www.selleckchem.com/products/Romidepsin-FK228.html to use antihistamines for allergic complaints and one was withdrawn because of a protocol violation (FEV1?LMTK2 Table?2). Fluticasone propionate significantly improved the PC20 AMP at 14?h but not at 26?h compared to placebo, the difference in doubling concentrations being 1.72 (0.70�C2.75) and 0.33 (?0.69�C1.34) at 14 and 26?h respectively. NLG919 No significant changes in the concentration of eNO were observed after FF or FP treatment at any time point (Table?2). Finally, no relationships were found between the level of FEV1 and improvement in PC20 AMP 2, 14 or 26?h after treatment with FP, FF or placebo. Of the 18 subjects who completed the study, a total of 44 adverse events were reported and there were no serious adverse events. The most frequently occurring adverse event was bronchospasm (33%), followed by dyspnea, dizziness, headache, nausea, palpitations and fatigue. None of the adverse events occurred more frequently during treatment with FF when compared to FP or placebo. Most of the adverse events were temporally associated with the AMP challenge procedure (dyspnea, dizziness, headache, nausea, palpitations and fatigue). Nine adverse events were considered to be related to the study medication by the investigator (either FP or placebo, no adverse events were judged to be related to FF). Sixteen subjects received concomitant medication (salbutamol) for either an adverse event (bronchoconstriction, dyspnea) or as rescue medication during the study. We present the first study investigating the efficacy and duration of action of a single dose of FF in the treatment of asthma.